Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
about
Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysisMoving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trialVirologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysisLopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use.Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD)The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data.Characterization of peripheral and mucosal immune responses in rhesus macaques on long-term tenofovir and emtricitabine combination antiretroviral therapy.Emerging antiretroviral drug resistance in sub-Saharan Africa: novel affordable technologies are needed to provide resistance testing for individual and public health benefits.Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children.Comparative efficacy of Lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trialsCreation of a Long-Acting Nanoformulated 2',3'-Dideoxy-3'-ThiacytidineComparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States.Pediatric antiretroviral therapy.Pharmacoeconomics of darunavir.Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation.Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.Structural equation modelling of viral tropism reveals its impact on achieving viral suppression within 6 months in treatment-naive HIV-1-infected patients after combination antiretroviral therapy.NRTI backbone in HIV treatment: will it remain relevant?Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada.Residual viremia in patients on antiretroviral therapy incorporating nevirapine is not associated with the gag-specific cellular immune response.
P2860
Q21999480-10EC54EE-48F5-46E5-BEA6-6C84868D3531Q28540037-8B6190E8-B7EC-4AED-A35A-46F2979C3213Q33624953-DF0C6F22-9A16-45C9-9320-825127071843Q34251223-F3647EB1-F3DD-4F69-A211-A5B58C789611Q34478840-9F3C861E-66CC-4D5C-BF36-29788E887431Q35743271-9FDA8C97-AFF4-4B3D-8AB5-C975B8E6C4B0Q36286733-184EF93F-57AF-4809-AA41-03C0CC7B5806Q36389032-9226496E-3253-487D-BF53-B9794C9435DFQ36669337-225DB945-E3B5-443E-BDE9-D20C9430AD73Q37029110-02221A23-D432-481A-BC1D-8D948ED3D7AAQ37296706-29A3CA9D-821C-400A-B5D3-674672611155Q37639081-961FA8DA-5617-419B-AAB6-92BE3460D1B6Q37782179-43EE3BD9-B517-4D15-B34C-98D040C55305Q37816389-3482EF87-6C9C-4BBD-B7C1-BB12526635EEQ37847151-DF3A18FE-8E09-4C46-81BB-0F9FEA76E9EBQ38040137-2CE88835-FF8B-4D8E-A670-A756CA663102Q38865547-B7C137EA-A53C-4B80-AFB3-B49A4DA98543Q39412054-46CAAAA2-6EC9-48E2-A953-294D58D6F8D0Q39533858-D64BE734-6833-45B2-85B0-4ED958521FA1Q40806577-44926669-0BB6-4627-BC07-A1197FD795C3Q42213902-5B857029-C980-4F5B-9A86-B41CE88E353FQ42263433-126E2302-C21A-48F4-9229-D9E9CDBD6A64
P2860
Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effects of nucleoside reverse ...... nical trials in 5168 patients.
@en
Effects of nucleoside reverse ...... nical trials in 5168 patients.
@nl
type
label
Effects of nucleoside reverse ...... nical trials in 5168 patients.
@en
Effects of nucleoside reverse ...... nical trials in 5168 patients.
@nl
prefLabel
Effects of nucleoside reverse ...... nical trials in 5168 patients.
@en
Effects of nucleoside reverse ...... nical trials in 5168 patients.
@nl
P1433
P1476
Effects of nucleoside reverse ...... nical trials in 5168 patients.
@en
P304
P356
10.1111/J.1468-1293.2009.00724.X
P577
2009-10-01T00:00:00Z